ScoreWhy is Vertex Pharmaceuticals, Inc. ?
1
Positive results in Dec 25
- OPERATING CASH FLOW(Y) Highest at USD 3,631.4 MM
- INTEREST COVERAGE RATIO(Q) Highest at 41,015.15
- NET PROFIT(Q) Highest at USD 1,242.74 MM
2
With ROE of 23.78%, it has a fair valuation with a 6.34 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -7.66%, its profits have risen by 8.9% ; the PEG ratio of the company is 2.5
3
High Institutional Holdings at 97.13%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 1.31% over the previous quarter.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Vertex Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Vertex Pharmaceuticals, Inc. for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Vertex Pharmaceuticals, Inc.
-7.66%
-0.10
35.64%
S&P 500
18.81%
0.98
19.26%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
14.23%
EBIT Growth (5y)
10.63%
EBIT to Interest (avg)
51.26
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.38
Sales to Capital Employed (avg)
0.64
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
97.13%
ROCE (avg)
80.88%
ROE (avg)
19.31%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
6.34
EV to EBIT
23.50
EV to EBITDA
22.52
EV to Capital Employed
9.22
EV to Sales
9.27
PEG Ratio
2.52
Dividend Yield
NA
ROCE (Latest)
39.22%
ROE (Latest)
23.78%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend11What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 3,631.4 MM
INTEREST COVERAGE RATIO(Q)
Highest at 41,015.15
NET PROFIT(Q)
Highest at USD 1,242.74 MM
RAW MATERIAL COST(Y)
Fallen by -0.26% (YoY
NET SALES(Q)
Highest at USD 3,227.1 MM
OPERATING PROFIT(Q)
Highest at USD 1,353.5 MM
PRE-TAX PROFIT(Q)
Highest at USD 1,388.7 MM
EPS(Q)
Highest at USD 4.65
-3What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.14 times
DEBT-EQUITY RATIO
(HY)
Highest at -24.51 %
Here's what is working for Vertex Pharmaceuticals, Inc.
Interest Coverage Ratio
Highest at 41,015.15
in the last five periodsMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Net Profit
Highest at USD 1,242.74 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD 3,631.4 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 3,227.1 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 1,353.5 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD 1,388.7 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
EPS
Highest at USD 4.65
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -0.26% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Vertex Pharmaceuticals, Inc.
Inventory Turnover Ratio
Lowest at 1.14 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debt-Equity Ratio
Highest at -24.51 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
